1. Introduction {#s0005}
===============

Arylamine *N*-acetyltransferases (E.C. 2.3.1.5) catalyze the *N*-acetylation of numerous arylamine and hydrazine drugs. *N*-Acetyltransferase 2 (NAT2) is subject to a genetic polymorphism in human populations and was identified following administration of isoniazid (INH) for the treatment of tuberculosis[@bib1]. As recently reviewed, numerous single nucleotide polymorphisms in the coding exon the *NAT2* gene, inherited as *NAT2* haplotypes and genotypes, confer rapid, intermediate, and slow acetylator phenotypes that modify the metabolism of arylamine and hydrazine drugs in human populations[@bib2]. The role of NAT2 and its genetic polymorphism in the metabolism and pharmacokinetic profile of INH has been reviewed[@bib3], [@bib4].

INH is extensively prescribed because of the high global incidence of tuberculosis with over 10 million new cases reported in 2015[@bib5]. Numerous studies have investigated the effect of *NAT2* genetic polymorphism in INH efficacy and toxicity in populations across the world[@bib2]. The extensive use of INH for the treatment and prevention of tuberculosis is compromised by INH-induced hepatotoxicity and liver failure[@bib6].

The role of the NAT2 acetylator polymorphism on INH hepatotoxicity has been extensively investigated. As reported in each of three recent reviews[@bib7], [@bib8], [@bib9], published reports on the role of the NAT2 acetylator polymorphism on INH hepatotoxicity have been inconsistent and controversial. INH hepatotoxicity has been investigated in the rat, mouse and rabbit, but the course and pattern of the hepatoxicity is much different from that observed in human populations and inconsistent and controversial results have been reported[@bib9], suggesting that INH hepatotoxicity in animal models is not informative for understanding INH hepatoxicity in humans.

Increased risk of INH-induced hepatoxicity initially was proposed in rapid NAT2 acetylators because of greater generation of hydrazine metabolites[@bib10] supported by several clinical studies reporting higher incidence of INH hepatotoxicity in rapid NAT2 acetylators[@bib10], [@bib11], [@bib12]. Recent meta-analyses of the role of NAT2 polymorphism on INH-induced hepatotoxicity have reported a higher frequency of INH-induced hepatotoxicity in NAT2 slow acetylators but no difference in risk between rapid and intermediate NAT2 acetylators[@bib7], [@bib8], [@bib13]. A very recent review of INH metabolism and hepatotoxicity concludes that the role of NAT2 acetylator polymorphism in INH hepatotoxicity remains controversial and poorly understood[@bib9].

As previously reviewed[@bib14], while investigations of drug metabolism and toxicity often are carried out in animal models, interspecies differences may preclude accurate prediction of drug metabolic profiles in humans. Although primary cultures of human hepatocytes can produce a metabolic profile similar to that found *in vivo*, the availability of primary cultures of human hepatocytes is limited. Cryopreservation techniques have been developed yielding a high percentage of viable and plateable hepatocytes[@bib15], [@bib16], [@bib17] to facilitate investigations using annotated cryopreserved human hepatocytes for use by laboratories across the world.

Cryopreserved human hepatocytes have been used for *in vitro* investigations into the metabolism of arylamine drugs and carcinogens[@bib18], [@bib19] and exploring relationships between acetylator genotype and phenotype[@bib20]. The purpose of our present study was to investigate the role of *NAT2* genetic polymorphism on INH *N*-acetylation in cryopreserved human hepatocytes obtained from rapid, intermediate and slow acetylators.

2. Materials and methods {#s0010}
========================

2.1. Source and processing of cryopreserved human hepatocytes {#s0015}
-------------------------------------------------------------

Cryopreserved hepatocyte samples obtained from humans were received from Bioreclamation IVT (Baltimore, MD, USA) and stored in liquid nitrogen until use. Hepatocyte samples were collected from consented donors under IRB approved protocols at their FDA licensed donor center (<http://www.bioreclamationivt.com/>). Hepatocytes were prepared from fresh human tissue with hepatocytes isolated and frozen within 24 h of organ removal. All hepatocytes are human transplant rejected. All hepatocytes were tested and are negative for hepatitis B and C and HIV 1 and 2. Hepatocytes were treated as containing human-derived materials as potentially infectious, as no known test methods can offer assurance that products derived from human tissues will not transmit infectious agents. Upon removal from liquid nitrogen, hepatocytes were thawed according to the manufacturer׳s instructions by warming a vial of the hepatocytes at 37 °C for 90 s and transferring to a 50 mL conical tube containing 45 mL of InVitroGRO HT medium (Bioreclamation IVT, USA). The cell suspension was centrifuged at 50 × *g* at room temperature for 5 min. The supernatant was discarded and cells washed once in ice-cold phosphate buffered saline (PBS) before lysing the cells in ice-cold 20 mmol/L NaPO~4~, 1 mmol/L dithiothreitol, 1 mmol/L EDTA, 0.2% Triton X-100, 1 mmol/L phenylmethylsulfonyl fluoride, 1 µmol/L pepstatin A, and 1 µg/mL aprotinin. The lysate was centrifuged at 15,000 × *g* for 20 min and the supernatant was aliquoted and stored at --70 °C. Protein concentrations in the lysates were determined using the Bio-Rad protein assay kit (Bio-Rad, Richmond, CA, USA). Hepatocyte used for all *in vitro* experiments were categorized at either cryosuspensions or cryoplateable hepatocytes. Hepatocytes used for *in situ* studies were categorized as cryoplateable and approved for studies involving drug metabolism.

2.2. NAT2 genotyping and assignment of acetylator phenotype {#s0020}
-----------------------------------------------------------

Prod. Type: FTPw?\>Genomic DNA was isolated from pelleted cells prepared from human cryopreserved hepatocyte samples as described above by using the QIAamp DNA Mini Kit (QIAGEN, Valencia, CA, USA) according to the manufacturer׳s instructions. The nomenclature and functional effects of single nucleotide polymorphisms present in various *NAT2* haplotypes and genotypes has been reviewed[@bib2], [@bib21]. *NAT2* genotypes and deduced phenotypes were determined as described previously[@bib21], [@bib22]. Controls (no DNA template) were run to ensure that there was no amplification of contaminating DNA. Individuals possessing two *NAT2* alleles associated with rapid acetylation activity (*NAT2*\**4*, *NAT2*\**12*, and *NAT2*\**13*) were classified as rapid acetylators; individuals possessing one of these alleles and one allele associated with slow acetylation activity (*NAT2*\**5*, *NAT2*\**6*, *NAT2*\**7*, and *NAT2*\**14*) were classified as intermediate acetylators, and those individuals that possessed two slow acetylation alleles were classified as slow acetylators. Cryopreserved hepatocytes with rapid, intermediate and slow *NAT2* acetylator genotype were selected at random for measurements of INH *N*-acetylation as described below. The individual *NAT2* genotype, gender, and ethnicity of each individual human cryopreserved hepatocyte sample is listed together with their respective INH *N*-acetyltransferase enzyme activity *in vitro* ([Table 1](#t0005){ref-type="table"}) and INH N-acetylation *in situ* ([Table 2](#t0010){ref-type="table"}).Table 1Isoniazid (INH) and *N*-(4-aminobenzoyl)-L-glutamic acid (ABG) *N*-acetyltransferase activities *in vitro* in human cryopreserved human hepatocyte samples.Table 1Sample ID*NAT2* genoytpeDeduced NAT2 phenotypeGenderEthnicityINH *N*-acetyltransferase activity[a](#tbl1fna){ref-type="table-fn"}ABG *N*-acetyltransferase activity[a](#tbl1fna){ref-type="table-fn"}FLA*NAT2\*4/\*4*RapidFemaleCaucasian0.3610.494HWG*NAT2\*4/\*4*RapidMaleCaucasian0.1830.358GPM*NAT2\*4/\*4*RapidMaleHispanic0.1550.388FXA*NAT2\*4/\*4*RapidFemaleHispanic0.1410.303XUA*NAT2\*4/\*13*RapidFemaleCaucasian0.0840.311VHU*NAT2\*4/\*5B*IntermediateFemaleAfrican0.0750.311UFN*NAT2\*4/\*5B*IntermediateMaleCaucasian0.1240.291ZCA*NAT2\*4/\*5B*IntermediateFemaleCaucasian0.0510.256ZQM*NAT2\*4/\*5A*IntermediateFemaleCaucasian0.0230.261OJE*NAT2\*4/\*6A*IntermediateFemaleCaucasian0.0570.446DVR*NAT2\*5B/\*5B*SlowFemaleCaucasian0.0420.329PFM*NAT2\*5B/\*5B*SlowMaleCaucasian0.0080.617ZFB*NAT2\*5B/\*6A*SlowFemaleCaucasian0.0440.413MFB*NAT2\*5A/\*6A*SlowMaleHispanic0.0050.438XMM*NAT2\*6A/\*6A*SlowMaleCaucasian0.0010.673[^1][^2]Table 2Acetyl-INH levels in human cryopreserved human hepatocytes.Table 2Sample ID*NAT2* genotypeDeduced NAT2 phenotypeGenderEthnicityAcetyl-INH level[a](#tbl2fna){ref-type="table-fn"}12.5 µmol/L INH100 µmol/L INHFWK*NAT2\*4/\*4*RapidFemaleCaucasian26.260.7ZFK*NAT2\*4/\*4*RapidMaleCaucasian33.472.8YXZ*NAT2\*4/\*4*RapidMaleHispanic18.348.6JZG*NAT2\*4/\*4*RapidMaleHispanic30.169.8FAO*NAT2\*4/\*4*RapidFemaleAfrican18.351.6ZFR*NAT2\*4/\*5B*IntermediateMaleCaucasian15.341.9TUG*NAT2\*4/\*5B*IntermediateMaleCaucasian22.560.1HUG*NAT2\*4/\*5B*IntermediateFemaleCaucasian10.233.5ASQ*NAT2\*4/\*5A*IntermediateFemaleCaucasian19.238.3NIQ*NAT2\*4/\*6A*IntermediateFemaleCaucasian12.135.6UFP*NAT2\*5B/\*6A*SlowFemaleCaucasian0.217.00DOO*NAT2\*5B/\*6A*SlowMaleCaucasian1.7013.20DNB*NAT2\*5B/\*6A*SlowMaleCaucasian0.172.00YNS*NAT2\*5A/\*6A*SlowMaleHispanic0.528.05UNF*NAT2\*6A/\*6A*SlowMaleAfrican1.100.85[^3][^4][^5]

2.3. Measurement of N-acetyltransferase activity in vitro {#s0025}
---------------------------------------------------------

Arylamine *N-*acetyltransferase activities were measured *in vitro* in reactions containing hepatocyte lysate (\< 2 mg of protein/mL prepared from samples previously identified as rapid, intermediate, or slow *NAT2* acetylator genotypes), 300 µmol/L INH or *N*-(4-aminobenzoyl)-L-glutamic acid (ABG) and 1 mmol/L acetyl coenzyme A (AcCoA) were incubated at 37 °C. Reactions were terminated by the addition of 1/10 volume of 1 mol/L acetic acid. The reaction tubes were centrifuged to precipitate protein. The amount of acetyl-product produced was determined following separation and quantitation by high performance liquid chromatography (HPLC). Separation of INH and acetyl-INH was accomplished using a 125 mm × 4 mm Lichrosher 100 RP-100 5 µm C18 HPLC column eluted with an isocratic gradient of 86% 25 mmol/L sodium phosphate, 10 mmol/L heptane sulfonate pH 3.0, 14% acetonitrile. Acetyl-INH was quantitated by measuring the absorbance at 266 nm. Retention times for INH and acetyl-INH were 2.63 and 2.93 min, respectively. The amount of acetyl-*N*-(4-aminobenzoyl)-L-glutamic acid produced was determined following separation and quantitation by HPLC. Separation of *N*-(4-aminobenzoyl)-L-glutamic acid and acetyl-*N*-(4-aminobenzoyl)-L-glutamic acid was accomplished using the same HPLC column described above eluted with a gradient of 100% 20 mmol/L sodium perchlorate pH 2.5/0% acetonitrile to 50% 20 mmol/L sodium perchlorate pH 2.5/50% acetonitrile over 5 min. *N*-(4-Aminobenzoyl)-L-glutamic acid and acetyl-*N*-(4-aminobenzoyl)-L-glutamic acid were quantitated by measuring the absorbance at 280 nm. Retention times were 8.17 and 8.83 min, respectively. The *NAT2* genotypes gender and ethnicity of the samples are shown in [Table 1](#t0005){ref-type="table"}.

2.4. Measurement of INH N-acetylation in situ {#s0030}
---------------------------------------------

Plateable cryopreserved human hepatocyte samples (different from those used above for *in vitro* investigations) previously identified as rapid, intermediate, or slow *NAT2* acetylator genotypes were thawed as described above and contents of the vial were transferred into a 15 mL conical tube containing 12 mL of InVitroGRO CP (Bioreclamation IVT) media pre-warmed to 37 °C. Cells (1.0 mL/well) were plated into Biocoat^®^ collagen-coated 12-well plates (BD labware, Bedford, MA, USA) and allowed to attach overnight. The next morning media was removed (dead cells, cell debri and non-adherent live cells were washed away and removed) and attached cells washed with 1 × PBS and replaced with fresh pre-warmed InVitroGRO CP media containing 12.5--200 µmol/L INH. Hepatocytes were incubated for up to 48 h after which media was removed and protein precipitated by addition of 1/10 volume of 1 mol/L acetic acid. Media was centrifuged at 15,000 × *g* for 10 min and supernatant used to quantitate acetyl-INH as described above. The determination of the number of live cells per sample were determined after drug incubation was complete and were counted using Z1/Dual (Beckman, Brea, CA, USA) to get live cell numbers to determine activity in nmoles of acetylated-product over 24 h per million cells.

2.5. Statistical analysis {#s0035}
-------------------------

Differences in *N*-acetylation rates among rapid, intermediate, and slow *NAT2* acetylator genotypes were tested for significance by one way analysis of variance across rapid, intermediate, and slow *NAT2* genotypes followed when significant (*P* \< 0.05) by Tukey-Kramer multiple comparisons tests between rapid, intermediate, and slow *NAT2* genotypes.

3. Results {#s0040}
==========

3.1. N-Acetyltransferase activity in vitro {#s0045}
------------------------------------------

*N*-acetylation rates of ABG *in vitro*, a substrate highly selective for human *N*-acetyltransferase 1 *versus* NAT2[@bib23] did not differ significantly (*P* \> 0.05) between rapid, intermediate, and slow NAT2 acetylator cryopreserved human hepatocytes ([Fig. 1](#f0005){ref-type="fig"}). In contrast, *N*-acetylation rates towards INH in the identical samples of cryopreserved human hepatocytes from rapid, intermediate, and slow NAT2 acetylators exhibited a robust and highly significant (*P* \< 0.005) *NAT2* genotype-dependent metabolism ([Fig. 1](#f0005){ref-type="fig"}).Figure 1*In vitro N-*acetyltransferase catalytic activities towards INH (A) and *N*-(4-aminobenzoyl)-L-glutamic acid (B) in cryopreserved human hepatocytes. Individual data points represent different human hepatocyte samples. Error bars illustrate mean ± S.E.M. in rapid, intermediate, and slow acetylators (*n* = 5). INH *N*-acetyltransferase activities differed significantly (*P* \< 0.005) between rapid, intermediate, and slow acetylators (rapid *vs.* intermediate *P* \< 0.05; rapid *vs.* slow *P* \< 0.01) whereas *N*-(4-aminobenzoyl)-L-glutamic acid *N*-acetyltransferase activities did not (*P* \> 0.05).Fig. 1

3.2. N-acetylation capacity in situ {#s0050}
-----------------------------------

*N*-acetylation of INH *in situ* was shown to be both INH concentration- and time-dependent up to concentrations of 100 µmol/L INH ([Fig. 2](#f0010){ref-type="fig"}) and 48 h incubation ([Fig. 3](#f0015){ref-type="fig"}) in the cryopreserved human hepatocytes. As shown in [Fig. 4](#f0020){ref-type="fig"}, robust and significant *NAT2* genotype-dependent patterns (rapid \> intermediate \> slow) were exhibited for the *N*-acetylation of INH *in situ* following 24 h incubations with either 12.5 (*P* = 0.0023) or 100 (*P* = 0.0002) µmol/L INH. Cytotoxicity of isoniazid over 24 h was tested by Alamar Blue and IC~50~ was determined to be greater than 1 mmol/L for both rapid and slow NAT2 acetylator hepatocytes which is much higher than the concentration used for the *N*-acetylation assays.Figure 2Concentration-dependent *N-*acetylation of INH in cryoplateable human hepatocytes. Cryoplateable human hepatocytes with a rapid *NAT2* genotype were plated on collagen coated 12-well plate and allowed to attach. After 24 h plating media was removed and replaced with media containing (0--200 µmol/L) INH for 24 h. The amount of acetyl-INH produced was measured in the media. Each data point is mean ± S.E.M. for three independent measurements. Data shows concentration-dependent increase in the production of INH.Fig. 2Figure 3Time-dependent *N-*acetylation of INH in cryoplateable human hepatocytes. Cryoplateable human hepatocytes with a rapid *NAT2* genotype were plated on collagen coated 12-well plate and allowed to attach. After 24 h plating media was removed and replaced with media containing 12.5 or 100 µmol/L INH. Cells were incubated with media containing INH for 0--48 h. The amount of acetyl-INH produced was measured in the media. Each data point is mean ± S.E.M. for three independent measurements. Data shows R-squared for goodness of fit for the time-dependent increase in the production of acetylated-INH was 0.9612 and 0.9599 for 12.5 and 100 µmol/L, respectively.Fig. 3Figure 4*N*-Acetylation of INH by cryoplateable human hepatocytes with rapid, intermediate or slow NAT2 acetylator genotypes. Individual data points represent different human hepatocyte samples. Error bars illustrate mean ± S.E.M. acetyl-INH levels in rapid, intermediate and slow acetylators (*n* = 5), following 24 h cell culture with 12.5 or 100 µmol/L INH. The levels of acetyl-INH differed significantly between the acetylator genotypes following incubation with 12.5 µmol/L (*P* =0.0023; rapid *vs.* intermediate *P* \< 0.05; intermediate *vs.* slow *P* \< 0.01) or 100 µmol/L (*P* = 0.0002; rapid *vs* intermediate *P* \< 0.05; intermediate *vs.* slow *P* \< 0.001) INH.Fig. 4

4. Discussion {#s0055}
=============

Robust *NAT2* genotype-dependent *N*-acetylation of INH was noted in human cryopreserved hepatocytes both *in vitro* and *in situ* following incubations at different concentrations of INH. The INH NAT2 enzyme activities in the rapid, intermediate, and slow *NAT2* genotype hepatocytes *in vitro* was quite consistent with NAT2 enzyme activities in cryopreserved human hepatocytes reported previously towards arylamine drugs including sulfamethazine and solithromycin and carcinogens including 4-aminobiphenyl[@bib18], [@bib19].

Although recent meta-analyses on the role of NAT2 acetylator polymorphism in INH hepatoxicity have reported increased risk among slow NAT2 acetylators, they have not as yet reported differences in risk between rapid and intermediate acetylators. Although the results of our study show significant differences in the *N*-acetylation of INH between rapid and intermediate acetylator hepatocytes both *in vitro* and *in situ*, the magnitude of the differences between rapid and intermediate acetylators were smaller than between intermediate and slow acetylators. Previous human *in vivo* studies have reported tri-modal distributions of INH *N*-acetylation reflective of rapid, intermediate, and slow NAT2 acetylator phenotypes[@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29].

A study conducted in Brazil found that the incidence of INH-induced hepatotoxicity differed among rapid (2.9%), intermediate (9.8%), and slow (22%) NAT2 acetylators[@bib30]. Other studies also have shown an effect of *NAT2* genotype on INH efficacy[@bib31], [@bib32] and pharmacogenetic-based therapy for tuberculosis has been proposed[@bib33], [@bib34], [@bib35], [@bib36], [@bib37]. Isoniazid concentrations of 3--6 μg/mL are the usual target for tuberculosis therapy[@bib36], [@bib37]. Our findings in cryopreserved human hepatocytes following incubations with 12.5 (1.71 µg/mL) and 100 (13.7 µg/mL) µmol/L INH reflect this therapeutic range of INH concentrations supporting use of *NAT2* genotype in isoniazid dosing strategies (*i.e*., rapid \> intermediate\> slow acetylators). An *NAT2* genotype-guided regime (INH dose 7.5 mg/kg for rapid acetylators; 5.0 mg/kg for intermediate acetylators; 2.5 mg/kg for slow acetylators) reduced INH-induced liver injury and -early treatment failure in a randomized controlled trial[@bib38]. Although it would be an over-extension to conclude that quantitative INH dosing strategies should be determined by INH *N*-acetylation rates in cryopreserved human hepatocytes, the results of the present study provide experimental metabolic support towards the use of *NAT2* genotype to guide INH dosing strategies in the treatment and prevention of tuberculosis.
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[^1]: Mean ± S.E.M. for rapid, intermediate, and slow NAT2 phenotypes are illustrated in [Fig. 1](#f0005){ref-type="fig"}.

[^2]: INH and ABG *N*-acetyltransferase activities in nmol/min/mg protein.

[^3]: Hepatocyte samples were incubated 24 h with 12.5 or 100 µmol/L INH.

[^4]: Mean ± S.E.M. for rapid, intermediate, and slow NAT2 phenotypes are illustrated in [Fig. 4](#f0020){ref-type="fig"}.

[^5]: Acetyl-INH levels are nmoles acetyl-INH/24 h/million cells.
